Shilpa Gupta, Director of Genitourinary Medical Oncology at Taussig Cancer Institute, Cleveland Clinic, shared on LinkedIn:
“Glad to share my thoughts on PSMaddition trial in Cleveland Clinic ConsultQD
mHSPC is no longer one – size – fits – all. With PSMA, BRCA and PTEN – directed options, treatment should be guided by disease volume, biology, comorbidities and patient goals.
Next questions: who benefits most, how to sequence it, and what the final survival data show?
Other articles featuring Shilpa Gupta on OncoDaily.